Commodities● Neutral
Zevra Jumps 29% on Miplyffa Orange Book Patent Listing
Zevra Therapeutics added a Miplyffa patent to the FDA Orange Book, extending exclusivity to 2039. The NP-C drug, approved last September, now covers roughly 900 potential U.S. patients.
Continue with
Shares of Zevra Therapeutics jumped 29% over two sessions after the company added a patent for its Niemann-Pick Disease Type C therapy Miplyffa to the FDA Orange Book. The drug's patent protection now extends to 2039, a filing showed.
The Orange Book listing strengthens Zevra's exclusivity position on Miplyffa, which won FDA approval in September 2024 as the first oral treatment for the rare genetic disorder. NP-C affects roughly 900 patients in the U.S., and the drug carries an annual list price near $500,000 before patient assistance programs.